Human Gene Set: GSE39820_CTRL_VS_IL1B_IL6_CD4_TCELL_UP


Standard name GSE39820_CTRL_VS_IL1B_IL6_CD4_TCELL_UP
Systematic name M5599
Brief description Genes up-regulated in comparison of untreated CD4 [GeneID=920] T cells versus those treated with IL1B [GeneID=3553] and IL6 [GeneID=3569].
Full description or abstract TGF-beta3 produced by developing Th17 cells induces highly pathogenic T cells that are functionally and molecularly distinct from TGF-beta1-induced Th17 cells. The microarray data represent a distinct molecular signature for pathogenic versus non-pathogenic Th17 cells.
Collection C7: Immunologic Signature
      IMMUNESIGDB: ImmuneSigDB
Source publication Pubmed 22961052   Authors: Lee Y,Awasthi A,Yosef N,Quintana FJ,Xiao S,Peters A,Wu C,Kleinewietfeld M,Kunder S,Hafler DA,Sobel RA,Regev A,Kuchroo VK
Exact source GSE39820_1555_200_UP
Related gene sets (show 21 additional gene sets from the source publication)

(show 390 gene sets from the same authors)
External links
Filtered by similarity ?
Source species Mus musculus
Contributed by Jernej Godec (Dana-Farber Cancer Institute)
Source platform or
identifier namespace		 HUMAN_GENE_SYMBOL
Dataset references (show 1 datasets)
Download gene set format: grp | gmt | xml | json | TSV metadata
Compute overlaps ? (show collections to investigate for overlap with this gene set)
Compendia expression profiles ? NG-CHM interactive heatmaps
(Please note that clustering takes a few seconds)
GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)

Legacy heatmaps (PNG)
GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)
Advanced query Further investigate these 199 genes
Gene families ? Categorize these 199 genes by gene family
Show members (show 200 source identifiers mapped to 199 genes)
Version history 7.3: Moved to ImmuneSigDB sub-collection.

See MSigDB license terms here. Please note that certain gene sets have special access terms.